Lyra Therapeutics Voluntarily Files for Delisting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Lyra Therapeutics announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission on Monday, April 20, 2026, to remove its common stock from listing and registration on The Nasdaq Stock Market. As previously disclosed, trading in the Company's common stock was suspended by Nasdaq on March 17, 2026. Although Nasdaq has indicated it intends to file its own Form 25 after all internal procedural periods have run, it has not yet done so. The Company is therefore voluntarily filing Form 25 in order to proceed with deregistration.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
